Is BDTX or GRDX more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Entero Therapeutics N/A -49.81% -11.02%

Do analysts rate GRDX or ETHZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRDX or ETHZ more profitable?

Entero Therapeutics' return on equity of -49.81% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Entero Therapeutics N/A -49.81% -11.02% Flag Ship Acquisition N/A -185.71% -83.12%

Do analysts rate KLRS or GRDX?

Kalaris Therapeutics presently has a consensus target price of $15.60, indicating a potential upside of 187.03%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is KLRS or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Kalaris Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Entero Therapeutics N/A -49.81% -11.02%

Do analysts prefer ANIX or GRDX?

Anixa Biosciences currently has a consensus price target of $8.50, suggesting a potential upside of 147.09%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than Entero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ANIX or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Anixa Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anixa Biosciences N/A -71.12% -62.88% Entero Therapeutics N/A -49.81% -11.02%

Do analysts rate LIXT or GRDX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LIXT or GRDX more profitable?

Entero Therapeutics' return on equity of -49.81% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Entero Therapeutics N/A -49.81% -11.02%

Entero Therapeutics (GRDX) Competitors

$3.73 -0.08 (-2.20%)

As of 01:42 PM Eastern

Compare

GRDX vs. BDTX, ETHZ, KLRS, ANIX, and LIXT

Should you buy Entero Therapeutics stock or one of its competitors? MarketBeat compares Entero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Entero Therapeutics include Black Diamond Therapeutics (BDTX), Flag Ship Acquisition (ETHZ), Kalaris Therapeutics (KLRS), Anixa Biosciences (ANIX), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.

How does Entero Therapeutics compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 9.3% of Black Diamond Therapeutics shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Black Diamond Therapeutics has higher revenue and earnings than Entero Therapeutics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.53	$22.37M	-$0.77	N/A
Entero Therapeutics	$40K	647.12	-$6.39M	-$1.88	N/A

Black Diamond Therapeutics presently has a consensus price target of $9.83, suggesting a potential upside of 427.26%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Black Diamond Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Entero Therapeutics' score of 1.87 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
Entero Therapeutics	Very Positive

Black Diamond Therapeutics' return on equity of -30.18% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Entero Therapeutics	N/A	-49.81%	-11.02%

Black Diamond Therapeutics has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the broader market.

Summary

Black Diamond Therapeutics beats Entero Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Flag Ship Acquisition?

Entero Therapeutics (NASDAQ:GRDX) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Entero Therapeutics and Entero Therapeutics both had 1 articles in the media. Entero Therapeutics' average media sentiment score of 1.87 beat Flag Ship Acquisition's score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Entero Therapeutics	Very Positive
Flag Ship Acquisition	Neutral

Entero Therapeutics' return on equity of -49.81% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entero Therapeutics	N/A	-49.81%	-11.02%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

Flag Ship Acquisition has higher revenue and earnings than Entero Therapeutics. Entero Therapeutics is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entero Therapeutics	$40K	647.12	-$6.39M	-$1.88	N/A
Flag Ship Acquisition	$4.11M	27.66	-$6.17M	-$159.65	N/A

Entero Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Summary

Entero Therapeutics beats Flag Ship Acquisition on 7 of the 12 factors compared between the two stocks.

How does Entero Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Kalaris Therapeutics had 5 more articles in the media than Entero Therapeutics. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Kalaris Therapeutics' score of 0.80 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Kalaris Therapeutics	Positive
Entero Therapeutics	Very Positive

Entero Therapeutics has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Entero Therapeutics	$40K	647.12	-$6.39M	-$1.88	N/A

Entero Therapeutics' return on equity of -49.81% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Entero Therapeutics	N/A	-49.81%	-11.02%

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Kalaris Therapeutics has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

Kalaris Therapeutics presently has a consensus target price of $15.60, indicating a potential upside of 187.03%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Entero Therapeutics beats Kalaris Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Anixa Biosciences had 5 more articles in the media than Entero Therapeutics. MarketBeat recorded 6 mentions for Anixa Biosciences and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Anixa Biosciences' score of 0.90 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Anixa Biosciences	Positive
Entero Therapeutics	Very Positive

Anixa Biosciences currently has a consensus price target of $8.50, suggesting a potential upside of 147.09%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anixa Biosciences is more favorable than Entero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Entero Therapeutics' return on equity of -49.81% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Entero Therapeutics	N/A	-49.81%	-11.02%

Anixa Biosciences has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Entero Therapeutics has lower revenue, but higher earnings than Anixa Biosciences. Anixa Biosciences is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	557.28	-$10.93M	-$0.31	N/A
Entero Therapeutics	$40K	647.12	-$6.39M	-$1.88	N/A

29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Anixa Biosciences beats Entero Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Entero Therapeutics compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Entero Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Lixte Biotechnology has higher earnings, but lower revenue than Entero Therapeutics. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Entero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Entero Therapeutics	$40K	647.12	-$6.39M	-$1.88	N/A

Lixte Biotechnology has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

In the previous week, Lixte Biotechnology had 2 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Lixte Biotechnology and 1 mentions for Entero Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat Lixte Biotechnology's score of 0.44 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Entero Therapeutics	Very Positive

5.1% of Lixte Biotechnology shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 9.5% of Lixte Biotechnology shares are held by insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Entero Therapeutics' return on equity of -49.81% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Entero Therapeutics	N/A	-49.81%	-11.02%

Summary

Entero Therapeutics beats Lixte Biotechnology on 7 of the 12 factors compared between the two stocks.

Get Entero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRDX vs. The Competition

Export

Metric	Entero Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$25.89M	$933.80M	$4.41B	$12.32B
Dividend Yield	N/A	4.84%	34.30%	8.87%
P/E Ratio	-1.99	1.48	23.71	24.00
Price / Sales	647.12	112.75	134.16	112.89
Price / Cash	N/A	20.06	164.96	59.89
Price / Book	0.50	8.60	12.09	6.22
Net Income	-$6.39M	-$3.14M	$121.47M	$331.73M
7 Day Performance	-16.76%	-2.91%	-2.26%	-2.01%
1 Month Performance	-24.32%	-1.55%	-3.11%	-1.36%
1 Year Performance	N/A	36.45%	9.51%	17.42%

Entero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRDX Entero Therapeutics	1.1118 of 5 stars	$3.73 -2.2%	N/A	N/A	$25.75M	$40K	N/A	9
BDTX Black Diamond Therapeutics	4.234 of 5 stars	$2.01 flat	$9.83 +389.2%	-40.5%	$115.18M	$70M	N/A	90	Positive News
ETHZ Flag Ship Acquisition	0.0341 of 5 stars	$6.02 +8.1%	N/A	N/A	$114.45M	$4.11M	N/A	7
KLRS Kalaris Therapeutics	4.4371 of 5 stars	$4.75 flat	$15.60 +228.4%	+87.4%	$113.01M	N/A	N/A	110	News Coverage Gap Down
ANIX Anixa Biosciences	4.1566 of 5 stars	$3.27 flat	$8.50 +159.9%	-1.2%	$111.26M	$210K	N/A	5	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRDX) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Entero Therapeutics (GRDX) Competitors

GRDX vs. BDTX, ETHZ, KLRS, ANIX, and LIXT

How does Entero Therapeutics compare to Black Diamond Therapeutics?

Summary

How does Entero Therapeutics compare to Flag Ship Acquisition?

Summary

How does Entero Therapeutics compare to Kalaris Therapeutics?

Summary

How does Entero Therapeutics compare to Anixa Biosciences?

Summary

How does Entero Therapeutics compare to Lixte Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Entero Therapeutics (GRDX) Competitors

GRDX vs. BDTX, ETHZ, KLRS, ANIX, and LIXT

How does Entero Therapeutics compare to Black Diamond Therapeutics?

Do institutionals and insiders have more ownership in BDTX or GRDX?

Which has stronger valuation & earnings, BDTX or GRDX?

Do analysts recommend BDTX or GRDX?

Does the media favor BDTX or GRDX?

Is BDTX or GRDX more profitable?

Which has more risk and volatility, BDTX or GRDX?

Summary

How does Entero Therapeutics compare to Flag Ship Acquisition?

Do insiders and institutionals hold more shares of GRDX or ETHZ?

Do analysts rate GRDX or ETHZ?

Does the media refer more to GRDX or ETHZ?

Is GRDX or ETHZ more profitable?

Which has better valuation and earnings, GRDX or ETHZ?

Which has more volatility and risk, GRDX or ETHZ?

Summary

How does Entero Therapeutics compare to Kalaris Therapeutics?

Does the media refer more to KLRS or GRDX?

Which has stronger valuation and earnings, KLRS or GRDX?

Is KLRS or GRDX more profitable?

Do institutionals & insiders believe in KLRS or GRDX?

Which has more risk & volatility, KLRS or GRDX?

Do analysts rate KLRS or GRDX?

Summary

How does Entero Therapeutics compare to Anixa Biosciences?

Does the media refer more to ANIX or GRDX?

Do analysts prefer ANIX or GRDX?

Is ANIX or GRDX more profitable?

Which has more volatility & risk, ANIX or GRDX?

Which has higher valuation & earnings, ANIX or GRDX?

Do institutionals & insiders have more ownership in ANIX or GRDX?

Summary

How does Entero Therapeutics compare to Lixte Biotechnology?

Do analysts rate LIXT or GRDX?

Which has preferable earnings and valuation, LIXT or GRDX?

Which has more risk and volatility, LIXT or GRDX?

Does the media refer more to LIXT or GRDX?

Do insiders & institutionals have more ownership in LIXT or GRDX?

Is LIXT or GRDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRDX vs. The Competition

Entero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools